［1］BEWERSDORF JP,ABDEL-WAHAB O.Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic［J］.Genes Dev,2022,36(5):259-277.
［2］DINARDO CD,WEI AH.How I treat acute myeloid leukemia in the era of new drugs［J］.Blood,2020,135(2):85-96.
［3］CORTES JE,MEHTA P.Determination of fitness and therapeutic options in older patients with acute myeloid leukemia［J］.Am J Hematol，2021，96（4）：493-507.
［4］韦梦红,夏海龙.维奈克拉联合阿扎胞苷治疗初诊不适合强化疗的急性髓系白血病患者的疗效观察［J］.中国现代医生,2024,62(01):74-77.
WEI MH,XIA HL.Vennakia combined with Azatidin therapy for the treatment of acute marrow leukemia patients who are not suitable for strong chemotherapy ［J］.Modern Chinese Doctors,2024,62(01):74-77.
［5］STAHI M,LU BY,KIM TK，et al．Novel therapies for acute myeloid leukemia:Are we finally breaking the deadlock［J］.Target Oncol，2017，12(4):413－447．
［6］ZEIDAN AM,FENAUX P,GOBBI M,et al.Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy［J］.Blood,2022,140(3):285-289.
［7］CHEN Y,CAO J,YE YZ,et al.Hypomethylating agents combined with low-dose chemotherapy for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy:a real-world clinical experience［J］.J Chemother,2022,28(13):1-8.
［8］POLLYEA DA,PRATZ K,LETAI A,et al.Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia:long term follow-up from a phase 1b study［J］.Am J Hematol,2021,96(2):208-217.
［9］MAITI A,DINARDO CD,QIAO W,et al.Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia:a propensity score-matched analysis［J］.Cancer,2021,127(22):4213-4220.
［10］刘霞霞,文晓玲,黎若祺，等.维奈克拉联合阿扎胞苷与“7+3”方案在新诊断老年急性髓系白血病中近期疗效的初步观察［J］.中国实验血液学杂志,2024,32(01):96-103.
LIU XX,WEN XL,LI RQ,et al．Vennakla combined with Azatidin and the "7+3" scheme in the newly diagnosed with the preliminary observation of the recent efficacy of acute myeloid leukemia ［J］.China Experimental Hematology,2024,32(01):96-103.
［11］GARCIA JS，SWORDS RT，ROBOZ GJ，et al．A systematic review of higher-risk myelodysplastic syndromes clinical trials to determinethe benchmark of azacitidine and explore alternative endpoints foroverall survival［J］．Leukemia Research，2021，104（1）：106555．
［12］KOISTINTN P,RATY R,ITALA M，et al．Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML):The nationwide AML-92 study by the Finnish Leukaemia Group［J］．Eur J Haematol，2007，6(78):477-486．
［13］张之南，沈悌．血液病诊断及疗效标准［M］．第3版．北京:科学技术出版社，2007:131-133，271．
ZHANG ZN，SHEN T．Agent efficacy criteria in diagnosis of hematological disease［M］．3rd ed．Beijing:Science Press，2007:131-133，271．
［14］刘霞,饶建华,朱丽娟，等.阿扎胞苷联合小剂量阿糖胞苷对治疗老年急性髓系白血病感染指标的影响［J］.中外医疗,2023,42(32):31-34.
LIU X,RAO JH,ZHU LJ,et al．The impact of Azatoside combined with small dose of gemlinoside on the treatment of acute myeloid leukemia infection in the treatment of elderly acute myelone ［J］.Chinese and Foreign Medical Treatment,2023,42(32):31-34.
［15］CHERRY EM,ABBOTT D,AMAYA M,et al.Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia［J］.Blood Adv,2021,5(24):5565-5573.
［16］MULLER AM，FLOREK M.5-Azacytidine/5-Azacitidine［J］.Recent Results Cancer Res，2014，201：299-324.
［17］杨懿春，石林，王建渝，等．含地西他滨方案治疗老年急性髓系白血病26例疗效分析［J］．临床血液学杂志，2018，31(5):50-52，55．
YANG YC，SHI L，WANG JY，et al．Therapeutic effect of decitabine regimen in the treatment of 26 patients with acute myeloid leukemia［J］．J Clin Hematol，2018，31(5):50-52，55．
［18］LIU W,ZHOU Z,CHEN L,et al.Comparison of azacitidine and decitabine in myelodysplastic syndromes and acutemyeloid leukemia:A network Meta-analysis ［J］.Clin Lymphoma Myeloma Leuk,2021,21(6):e530-e544.
［19］王共爱，薛克伟，李淑美，等.阿扎胞苷联合CAG方案治疗复发难治急性髓系白血病临床效果分析［J］.白血病·淋巴瘤，2020，29（3）：157-159.
WANG GA,XUE KW,LI SM,et al．Clinical efficacy analysis of azacitidine combined with CAG regimen in the treatment of relapsed and refractory acute myeloid leukemia ［J］.Leukemia·Lymphoma,2020,29(3):157-159.
［20］李舒心,陈嘉媛,惠岩,等.高三尖杉酯碱对CEBPA蛋白表达的作用及机制研究［J］.中国实验血液学杂志,2023,31(05):1257-1262.
LI SX,CHEN JY,HUI Y,et al．The role and mechanism of high-tech fir ester-alkali on CEBPA protein ［J］.China Experimental Hematology Magazine,2023,31(05):1257-1262.
［21］吴迪炯，叶宝东，沈建平，等．小剂量HA/HAA方案诱导治疗老年急性髓系白血病临床观察［J］．中华血液学杂志，2014，35(3):256-259．
WU DJ，YE BD，SHEN JP，et al．Clinical observation of low-dose HA/HAA regimen in the treatment of acute myeloid leukemia in the elderly［J］．Chin J Hematol，2014，35(3):256-259．
［22］YAMADA K，FURUSAWA S，SAITO K，et al．Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia:A pilot study［J］．Leukemia，1995，9(1):10-14．
［23］闫春艳,田冬华,宋君君,等.地西他滨联合CAG方案治疗老年急性髓系白血病患者的疗效［J］.癌症进展,2023,21(17):1967-1969.
YAN CY,TIAN DH,SONG JJ,et al．The efficacy of decitabine and CAG solution to treat patients with acute myeloid leukemia ［J］.Cancer Progress,2023,21(17):1967-1969.
［24］张飞,戚玉杨,陈丽丽,等.不同剂量地西他滨联合减剂量HAG治疗中高危MDS及老年AML患者的有效性和安全性回顾分析［J］.哈尔滨医科大学学报,2023,57(02):169-172.
ZHANG F,QI YY,CHEN LL,et al.Retrospective analysis of the efficacy and safety of different doses of dexamethasone combined with reduced dose HAG in the treatment of high-risk MDS and elderly AML patients ［J］.Journal of Harbin Medical University,2023,57 (02):169-172.